Comparison of Treatment Outcomes Between First-Line Chemotherapy With or Without Bevacizumab for Advanced Ovarian Clear Cell Carcinoma (Tohoku Gynecologic Cancer Unit: TGCU-RS001A Study).

Autor: Shoji T; Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan., Takatori E; Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan., Nagasawa T; Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan., Kagabu M; Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan., Baba T; Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan., Shigeto T; Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, Hirosaki 036-8563, Japan., Matsumura Y; Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, Hirosaki 036-8563, Japan., Shimizu D; Department of Obstetrics and Gynecology, Akita University Graduate School of Medicine, Akita 010-8543, Japan., Terada Y; Department of Obstetrics and Gynecology, Akita University Graduate School of Medicine, Akita 010-8543, Japan., Seino M; Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata 990-9585, Japan., Ohta T; Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata 990-9585, Japan., Nagase S; Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata 990-9585, Japan., Shigeta S; Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan., Tokunaga H; Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan., Shimada M; Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan., Kaiho-Sakuma M; Department of Gynecology, Miyagi Cancer Center, Natori 981-1293, Japan., Furukawa S; Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan., Soeda S; Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan., Watanabe T; Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan., Takahashi F; Department of Information Science, Iwate Medical University, Yahaba 028-3694, Japan., Yokoyama Y; Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, Hirosaki 036-8563, Japan.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2024 Nov 12; Vol. 16 (22). Date of Electronic Publication: 2024 Nov 12.
DOI: 10.3390/cancers16223801
Abstrakt: Objective : The usefulness of bevacizumab (BEV) as first-line chemotherapy for advanced ovarian clear cell carcinoma (CCC) was retrospectively evaluated at Tohoku Gynecologic Cancer Unit institutions. Patients and Methods : A total of 81 patients (52 patients without BEV and 29 with BEV) with advanced ovarian CCC who received initial platinum-based chemotherapy were enrolled. We selected 26 patients each without and with BEV according to propensity score matching methods, and compared the platinum-resistant recurrence rate, response rate, progression-free survival (PFS), overall survival (OS), and adverse events between the two groups. Results : The objective response rates for the patients with measurable disease in the non-BEV and BEV groups were 60.0% and 95.5%, respectively ( p = 0.007). The recurrence of platinum-resistant patients was observed in 50.0% of the non-BEV group and 23.1% of the BEV group ( p = 0.117). The median PFS was 12 and 22 months, respectively ( p = 0.034), and the median OS was 32 and 47 months, respectively ( p = 0.223). In the BEV group, grade 3 hypertension and proteinuria occurred in two patients, and thrombosis and carboplatin hypersensitivity occurred in one patient. Grade 4 gastrointestinal perforation occurred in one patient. Conclusions : First-line chemotherapy with BEV in advanced CCC showed the potential for high response rates and improved PFS.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje